216 related articles for article (PubMed ID: 34250422)
1. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250422
[TBL] [Abstract][Full Text] [Related]
2. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
3. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
4. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
[TBL] [Abstract][Full Text] [Related]
5. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract][Full Text] [Related]
6. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
7. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
8. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract][Full Text] [Related]
10. Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer.
Tripathi N; Thomas VM; Sayegh N; Gebrael G; Chigarira B; Jo Y; Li H; Sahu KK; Nussenzveig R; Nordblad B; Swami U; Agarwal N; Maughan BL
Prostate; 2023 Dec; 83(16):1602-1609. PubMed ID: 37644774
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
15. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
16. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
18. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
19. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
20. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
